SARS-CoV-2 infections in patients enrolled on the Children's Oncology Group standard-risk B-cell acute lymphoblastic leukemia trial, AALL1731
eJHaem
; 2023.
Article
in English
| EMBASE | ID: covidwho-2314309
ABSTRACT
Hematologic malignancy is a risk factor for severe coronavirus disease 2019 (COVID-19) in adults;however, data specific to children with leukemia are limited. High-quality infectious adverse event data from the ongoing Children's Oncology Group (COG) standard-risk B acute lymphoblastic leukemia/lymphoma (ALL/LLy) trial, AALL1731, were analyzed to provide a disease-specific estimate of SARS-CoV-2 infection outcomes in pediatric ALL. Of 253 patients with reported infections, the majority (77.1%) were asymptomatic or mildly symptomatic (CTCAE grade 1/2) and there was a single COVID-19-related death. These data suggest SARS-CoV-2 infection does not confer substantial morbidity among young patients with B-lymphoblastic leukemia/lymphoma (B-ALL/LLy).Copyright © 2023 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.
b-all; pediatrics; SARS-CoV-2; acute lymphoblastic leukemia; article; Burkitt lymphoma; cancer patient; child; controlled study; coronavirus disease 2019; female; human; lymphoblastoma; major clinical study; male; morbidity; nonhuman; outcome assessment; risk assessment; Severe acute respiratory syndrome coronavirus 2
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Prognostic study
/
Randomized controlled trials
Language:
English
Journal:
EJHaem
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS